Bristol-Myers Squibb's trading volume on March 13 was $555 million, ranking 197th among U.S. stocks on that day.

On March 13, 2026, the trading value of Bristol-Myers Squibb (BMY) was $555 million, ranking 197th among U.S. stocks that day. The trading value was down 8.26% from the previous day, and the trading volume on the day was 9.3868 million.

Bristol-Myers Squibb (BMY) rose 0.22% on March 13, 2026, to $59.08. Over the past 5 trading days, the stock fell 2.01%, the entire March declined 5.27%, it is up 9.53% year-to-date, and it fell 1.99% over the past 52 weeks.

If the company has been listed for less than 52 weeks, the 52-week gain/loss is calculated as the change from the listing date to now (the same applies to listings of less than 1 month or fewer than 5 trading days).

Bristol-Myers Squibb Company was incorporated in August 1933 in Delaware, United States. It originated from a company founded in New York in 1887 and was renamed in 1989 due to a merger. As a biopharmaceutical company, Bristol-Myers Squibb focuses on the discovery, development, licensing, manufacturing, marketing, and sales of innovative medicines to combat serious diseases. The company’s strategic approach combines the resources and scale of large pharmaceutical companies with the flexibility and innovation focus unique to the biotechnology industry. Bristol-Myers Squibb prioritizes transformative drugs in areas including oncology, hematology, immunology, cardiovascular, and neuroscience, aiming to deliver long-term value and competitive advantage. As a global research-based pharmaceutical company, Bristol-Myers Squibb’s products are sold worldwide, serving various entities including wholesalers, distributors, and specialty pharmacies, and maintaining significant production operations in multiple countries.